Skip to content
Head to head

Protagonist Therapeutics vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: PTGX · VRTX

Updated 8 minutes ago

1-year performance, rebased to 100

PTGX +43.2%VRTX +18.7%
Protagonist Therapeutics edges it on the scoreable measures. Protagonist Therapeutics has the highest Quant Rating (84); Protagonist Therapeutics has done best over the past year (+44%); Protagonist Therapeutics trades cheapest on trailing earnings.
PTGXVRTX
Snapshot
SectorBiotechnologyBiotechnology
Last price121.40515.02
Change today-2.11%-1.08%
1-year return+44.2%+22.0%
Market cap$7.92B$130.58B
52-week range77.00 – 160.81412.27 – 568.67
Valuation
P/E (TTM)25.6733.14
P/E percentile, own 5-yr range78th99th
P/B7.306.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-2.0515.32
Net profit (TTM)$-133.80M$3.88B
Revenue (TTM)$551.69M$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+5723.6%+11.8%
Gross margin--85.5%
Operating margin58.6%33.1%
Net margin62.0%30.7%
Free cash flow (TTM)$109.15M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership122.4%96.8%
Insider activity (12mo)17 buy / 33 sell28 buy / 22 sell
Short interest (% of float)15.8%1.9%
Analyst consensus100% buy (13)95% buy / 5% hold (21)
Analyst price target$180 (+48%)$624 (+21%)
StockVane view
StockVane Quant RatingC (84)C (68)
Company
Employees1326,400
Founded20061989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.